Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation

Conference call and webcast scheduled on Sunday, June 4, 2023 at 6:00 p.m. CT

BRISBANE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the publication of three abstracts on the American Society of Clinical Oncology (ASCO) website.

Dr. Lindsay Kilburn of Children’s National Hospital will present new and updated clinical data from the registrational FIREFLY-1 trial on June 4, 2023 during an oral session from 12:09 -12:21 p.m. CT at the ASCO Annual Meeting. The presentation will include updated overall response rate, duration of response, and safety data, including evaluations by RANO-HGG, RAPNO-LGG and RANO-LGG criteria. Previously released data as of September 28, 2022 is reflected in the abstract published today. The presentation will be available on the Day One investor website shortly after the live presentation, with a conference call and webcast to follow later that evening.

Oral Presentation Details
Title: Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.
Abstract Number: 10004
Abstract Session: Pediatric Oncology I
Date/Time: June 4, 2023, 12:09 - 12:21 p.m. CT
Presenter: Lindsay Kilburn, M.D., Neuro-Oncology Center for Cancer and Blood Disorders, Children’s National Medical Center

In addition, two posters will be presented on tovorafenib and healthcare resource data:
Poster Presentation Details
Title: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
Abstract Number: TPS10067
Abstract Session: Pediatric Oncology
Date/Time: June 5, 2023, 1:15 - 4:15 p.m. CT
Presenter: Cornelis M. van Tilburg, MD, PhD, Hopp Children’s Cancer Center Heidelberg, Heidelberg University Hospital and German Cancer Research Center  

Title: Healthcare resource use for pediatric low-grade glioma care: A cohort of linked electronic health records and claims data.
Abstract Number: 10038
Abstract Session: Pediatric Oncology
Date/Time: June 5, 2023, 1:15 - 4:15 p.m. CT
Presenter: Tab Cooney, MD, Day One Biopharmaceuticals

Day One will also have a Medical Information booth at the 2023 ASCO Annual Meeting at booth number 27155.